Stock Track | Vir Biotechnology Plunges 5.06% Post-Market Following $200 Million Stock Offering Announcement

Stock Track02-25

Vir Biotechnology, Inc. (VIR) experienced a 24-hour plunge of 5.06% in post-market trading on Tuesday, following a significant rally during the regular session.

The decline came after the company announced plans for a $200 million public offering of common stock. Equity offerings often lead to stock price pressure due to dilution concerns, as the increase in shares outstanding can reduce existing shareholders' ownership percentages.

This post-market drop followed a strong intraday performance where Vir Biotechnology's stock had soared after reporting better-than-expected fourth-quarter results and announcing a strategic collaboration with Astellas Pharma to develop and commercialize its prostate cancer drug, VIR-5500.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1135785944?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-25 09:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1135785944","market":"nz","top_or_hot":-1,"title":"Stock Track | Vir Biotechnology Plunges 5.06% Post-Market Following $200 Million Stock Offering Announcement","media":"Stock Track","content":"<p>Vir Biotechnology, Inc. (VIR) experienced a 24-hour plunge of 5.06% in post-market trading on Tuesday, following a significant rally during the regular session.</p><p>The decline came after the company announced plans for a $200 million public offering of common stock. Equity offerings often lead to stock price pressure due to dilution concerns, as the increase in shares outstanding can reduce existing shareholders' ownership percentages.</p><p>This post-market drop followed a strong intraday performance where Vir Biotechnology's stock had soared after reporting better-than-expected fourth-quarter results and announcing a strategic collaboration with Astellas Pharma to develop and commercialize its prostate cancer drug, VIR-5500.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Vir Biotechnology Plunges 5.06% Post-Market Following $200 Million Stock Offering Announcement</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Vir Biotechnology Plunges 5.06% Post-Market Following $200 Million Stock Offering Announcement\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-25 09:55</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Vir Biotechnology, Inc. (VIR) experienced a 24-hour plunge of 5.06% in post-market trading on Tuesday, following a significant rally during the regular session.</p><p>The decline came after the company announced plans for a $200 million public offering of common stock. Equity offerings often lead to stock price pressure due to dilution concerns, as the increase in shares outstanding can reduce existing shareholders' ownership percentages.</p><p>This post-market drop followed a strong intraday performance where Vir Biotechnology's stock had soared after reporting better-than-expected fourth-quarter results and announcing a strategic collaboration with Astellas Pharma to develop and commercialize its prostate cancer drug, VIR-5500.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VIR","symbol_name":"Vir Biotechnology, Inc.","start_time":0,"source_url":"","article_id":"1135785944","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1135785944","pubTimestamp":1771984504,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Vir Biotechnology, Inc. (VIR) experienced a 24-hour plunge of 5.06% in post-market trading on Tuesday, following a significant rally during the regular session.The decline came after the company...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VIR":"Vir Biotechnology, Inc."},"translate_title":"个股追踪|宣布发行2亿美元股票后Vir Biotechnology盘后暴跌5.06%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VIR":1},"content_text":"Vir Biotechnology, Inc. (VIR) experienced a 24-hour plunge of 5.06% in post-market trading on Tuesday, following a significant rally during the regular session.The decline came after the company announced plans for a $200 million public offering of common stock. Equity offerings often lead to stock price pressure due to dilution concerns, as the increase in shares outstanding can reduce existing shareholders' ownership percentages.This post-market drop followed a strong intraday performance where Vir Biotechnology's stock had soared after reporting better-than-expected fourth-quarter results and announcing a strategic collaboration with Astellas Pharma to develop and commercialize its prostate cancer drug, VIR-5500.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1135785944","isCrawlerRequest":true}